Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Novo Nordisk share price rose nearly 5% on August 18, 2025. The hike came after the US Food and Drug Administration granted ...

GoodRx (NASDAQ:GDRX) jumped 18% after revealing a partnership with Novo Nordisk (NYSE:NVO) to offer Ozempic and Wegovy to ...

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

Investors eyed risks around a high-stakes US-Ukraine meeting, kicking off a week dominated by a Federal Reserve speech that ...

GoodRx Stock Spikes 35% on Novo Nordisk Collaboration. They’re Offering Ozempic for $499 a Month.

Pharmaceutical powerhouse Novo Nordisk (NYSE:NVO) is charging 3.1% higher to trade at $54.10, after its weight-loss drug ...

GoodRx is collaborating with Novo Nordisk to offer its weight-loss drugs to self-paying patients at lower costs. The prescription-drug provider said Monday that all strengths of Ozempic and Wegovy ...

An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...

CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on Novo Nordisk. U.S. Issues New Travel Warning as ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a [form of liver disease]( ...